Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors

Autor: Markus Joerger, Reno Debets, Edwin A. Basak, Daan P. Hurkmans, Cor H. van der Leest, Sebastiaan D.T. Sassen, Karlijn de Joode, Lisanne Putter, Annemarie J.M. Wijkhuijs, Birgit C.P. Koch, Marco W.J. Schreurs, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Stijn L.W. Koolen

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)

Background Dosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors affecting PK and

Externí odkaz: https://doaj.org/article/91e30061d9b14b0499f8091d36100a62

CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab

Autor: Andre Kunert, Edwin A. Basak, Daan P. Hurkmans, Hayri E. Balcioglu, Yarne Klaver, Mandy van Brakel, Astrid A. M. Oostvogels, Cor H. J. Lamers, Sander Bins, Stijn L. W. Koolen, Astrid A. M. van der Veldt, Stefan Sleijfer, Ron H. J. Mathijssen, Joachim G. J. V. Aerts, Reno Debets

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)

Abstract Background Checkpoint inhibitors have become standard care of treatment for non-small cell lung cancer (NSCLC), yet only a limited fraction of patients experiences durable clinical benefit, highlighting the need for markers to stratify patie

Externí odkaz: https://doaj.org/article/85ac7d6b829b414e9203975733252de9

Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment

Autor: Edwin A. Basak, Niels S. Vermeer, Karlijn de Joode, Daan P. Hurkmans, Dorian E.M. Velthuis, Esther Oomen-de Hoop, Marco W.J. Schreurs, Sander Bins, Stijn L.W. Koolen, Reno Debets, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Arjen Joosse, Ron H.J. Mathijssen

Publikováno v: European Journal of Cancer, 174, 113-120. Elsevier Ltd.

AIM: With increasing use of immune checkpoint inhibitors (ICIs) more patients will develop severe and potentially life-threatening immune-related adverse events (irAEs). So far, predictive models for the occurrence of grade ≥3 irAEs are lacking. Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412001a708378502415a952c5d8415ce
https://doi.org/10.1016/j.ejca.2022.07.015

Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer

Autor: Astrid A M van der Veldt, Esther Oomen-de Hoop, Stijn L.W. Koolen, Daan P. Hurkmans, Ilse den Besten, Edwin A. Basak, Marco W.J. Schreurs, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Annemarie J.M. Wijkhuijs, Reno Debets, Stefan Sleijfer, Sander Bins

Publikováno v: European Journal of Cancer, 109, 12-20. Elsevier Ltd.

Introduction Nivolumab treatment is subject to large interpatient variability in both efficacy and toxicity, which may partly be explained by differences in nivolumab exposure. Exposure–response relationships in regular healthcare have not been ext

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa8136f63400117cbb3ee0e0e217110
https://doi.org/10.1016/j.ejca.2018.12.008

Blood-based kinase activity profiling

Autor: Joachim G.J.V. Aerts, Els M. E. Verdegaal, Reno Debets, Ellen Kapiteijn, Ron H.J. Mathijssen, Mandy van Brakel, Reinhard Dummer, Rik de Wijn, John P. Groten, Harmen J.G. van de Werken, Mitchell P. Levesque, Dianne M.A. van den Heuvel, Edwin A. Basak, Cor H. J. Lamers, Marij J. P. Welters, Sjoerd H. van der Burg, Daan P. Hurkmans, Rob Ruijtenbeek, Lies Hovestad, Herbert M Pinedo, Sabrina A. Hogan

Publikováno v: Journal for ImmunoTherapy of Cancer, 8(2):e001607. BioMed Central Ltd.
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, 8(2). BMJ PUBLISHING GROUP
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

BackgroundMany cancer patients do not obtain clinical benefit from immune checkpoint inhibition. Checkpoint blockade targets T cells, suggesting that tyrosine kinase activity profiling of baseline peripheral blood mononuclear cells may predict clinic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75f50b4ba6b119b5f029d84a4c81d150
https://pure.eur.nl/en/publications/2106b26b-a581-4468-9d95-68a84487825e